Navigation Links
Synvista Therapeutics' Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
Date:10/25/2007

"We look forward to future research efforts to further elucidate the role of AGEs in gastrointestinal complications including diabetic intestinal dysfunction, diabetic enteropathy and diabetic gastroparesis and the role that alagebrium may play in those disease."

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing small molecule drugs to treat and prevent cardiovascular disease and to treat nephropathy in people with diabetes. The Company has identified several product candidates that it believes represent novel approaches to some of the largest pharmaceutical markets. The Company's portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. These compounds metabolize lipid peroxides and have the potential to limit myocardial damage subsequent to a myocardial infarction. The Company is developing a clinical diagnostic test, based on cardiovascular risk assessment, using Haptoglobin characterization, to identify patients at high risk for cardiovascular complications of diabetes.

Synvista Therapeutics also is developing alagebrium, a proposed breaker of AGEs for the treatment of diastolic heart failure. This disease represents a rapidly growing market of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failure and nephropathy, among others. Alagebrium has been tested in approximately 1,000 patients in multiple Phase 1 and Phase 2 clinical trials, allowing Synvista Therapeutics to assemble a sizeable human safety database. For more information, please visit the Company's website at http://www.synvista.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties in
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)...  With a vision to ensure safety and ... Pharmaceutical and Biotech manufacturer selects and implements the ... to protect their animal health brand.  ... Photo - http://photos.prnewswire.com/prnh/20141021/153439 ... by the Xyntek and Antares solution is an ...
(Date:10/22/2014)... ST. LOUIS , Oct. 21, 2014 /PRNewswire-USNewswire/ ... are often subtle or unnoticed, but new technology, ... patient outcomes and leading to earlier detection of ... now affects 29 million Americans. If left untreated, ... or even blindness. Recently, optometric ...
(Date:10/22/2014)... WESTMINSTER, Colo. , Oct. 22, 2014   ... class of infusion systems designed to maximize targeted delivery ... is pleased to announce that oncologist John R. ... Norris Comprehensive Cancer Center, and surgical oncologist Steven ... Center have joined the Company,s Scientific Advisory Board (SAB).  ...
Breaking Medicine Technology:Xyntek and Antares Serialization Solution Protects Pets Too! 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2
... Findings from a,trial of the accuracy of CT ... pre-cancerous polyps and colorectal cancers,coordinated by the American ... issues for the public about colorectal cancer,screening using ... need for follow-up,with complete colonoscopy in many cases, ...
... The Department of,Justice announced today that it will ... Cancer (CRC) to develop and publicize model contract ... The Department said,the language is not likely to ... efficiency in contract negotiations, potentially reducing costs,and shortening ...
Cached Medicine Technology:Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities 2Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities 3Justice Department Will Not Oppose CEO Roundtable on Cancer's Proposal 2
(Date:10/25/2014)... Raleigh, NC (PRWEB) October 25, 2014 ... patient who continued to receive pemetrexed (Alimta), after his ... to read the full story , just posted on ... study from Uji Tokushukai Medical Center in Japan suggests ... for mesothelioma patients who cannot tolerate higher ...
(Date:10/25/2014)... Steven Reinberg HealthDay Reporter ... virus that causes common cold sores -- herpes simplex -- ... Swedish researchers suggest. In fact, being a carrier of ... Alzheimer,s disease, the researchers found. "The identification of ... disorder is a breakthrough," said lead researcher Dr. Hugo Lovheim, ...
(Date:10/25/2014)... Oct. 23, 2014 (HealthDay News) -- A large influx ... Africa is to avoid tens of thousands of deaths ... University researchers predict. Using a specially designed ... of the outbreak in just one densely populated county ... capital city of Monrovia. The researchers said that ...
(Date:10/25/2014)... 2014 (HealthDay News) -- October,s shorter, darker days can ... disorder, according to an expert. People affected ... overly tired, lack motivation and even have trouble getting ... to suicide, said Dr. Angelos Halaris, a professor in ... University Chicago Stitch School of Medicine. "Seasonal affective ...
(Date:10/22/2014)... On October 22, CBS will air ... diseases both fictional and real. The Charles E ... committed to advocacy and philanthropy in the battle against ... opportunity to impart truth and clarity about this misunderstood ... many misconceptions about Morgellons Disease (MD) and ...
Breaking Medicine News(10 mins):Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3
... ... to the position of Chief Operating Officer. She brings to the position more than ... business process review, performance management, organizational development, and quality assurance. , ... Columbus, OH (Vocus) September 11, 2009 ...
... , , , , ... costs are the single biggest economic concern facing American businesses, according to ... , Nearly 90% of those polled cite health care costs ... or energy costs. , , Without reform, 86% of ...
... from electronic assistance, researchers say , FRIDAY, Sept. 11 ... people can, new research suggests. , The findings may ... hard-of-hearing learn to read lips, according to researchers from ... compared the accuracy of an automated lip-reading machine to ...
... Reducing Americans, average intake of sodium to the amount recommended ... $18 billion annually in avoided health care costs and improve ... a new RAND Corporation study. The study estimates that ... high blood pressure nationally and extend the lives of thousands ...
... Sept. 11 Nuvilex, Inc. (OTC Bulletin Board: NVLX), ... partner, has informed the company that Reme-Flu(TM) has been ... for helping to prevent and treat flu-like symptoms resulting ... consists of a two-part protocol. Part one contains ...
... , , MISSISSAUGA, Ontario, Sept. 11 ... into an agreement with The Investor Relations Group, Inc. ("IRG"), pursuant ... services for the Company in accordance with the terms of the ... inquiries directly to IRG. , , "We are ...
Cached Medicine News:Health News:CBCA Administrators, Inc. Promotes Cindy Sonnen to Chief Operating Officer 2Health News:Poll Shows Solid Business Support for Health Care Reform 2Health News:Poll Shows Solid Business Support for Health Care Reform 3Health News:Computers Might Make Learning Lip Reading Easier 2Health News:Lowering sodium consumption could save US $18 billion annually in health costs, study finds 2Health News:Nuvilex, Inc. Announces Reme-Flu(TM) as Trade Name for All-Natural Flu Remedy Formula 2Health News:Nuvilex, Inc. Announces Reme-Flu(TM) as Trade Name for All-Natural Flu Remedy Formula 3Health News:JAG Media Holdings, Inc. Announces Agreement with The Investor Relations Group, Inc. 2
The soft silicone design promotes patient comfort. , ,Bivona® laryngectomy tubes feature a soft compliant silicone design for patient comfort....
Manufactured with a radiopaque line running down the length of the tube, position can be easily visualized by x-ray....
... vertical length tubes are often indicated ... stenosis, and tracheal malacia. Available in ... two independently inflatable cuffs. Greater flexibility ... since cuff sites can be alternated, ...
... It has been estimated that in excess ... special needs that require a specialized tracheostomy ... Tubes are soft, flexible, and can adapt ... patient including those requiring:, extra horizontal ...
Medicine Products: